Seroprevalence of Specific SARS-CoV-2 Antibodies during Omicron BA.5 Wave, Portugal, April-June 2022
- PMID: 36732078
- PMCID: PMC9973687
- DOI: 10.3201/eid2903.221546
Seroprevalence of Specific SARS-CoV-2 Antibodies during Omicron BA.5 Wave, Portugal, April-June 2022
Abstract
After the rapid spread of SARS-CoV-2 BA.5 Omicron lineage in Portugal, we developed a seroepidemiologic survey based on a sample of 3,825 residents. Results indicated that from April 27 through June 8, 2022, the estimated seroprevalence of SARS-CoV-2 nucleocapsid or spike IgG was 95.8%, which indicates a high level of protection.
Keywords: 2019 novel coronavirus disease; BA.5; COVID-19; IgG; Omicron; Portugal; SARS-CoV-2; coronavirus disease; respiratory infections; seroepidemiological survey; seroprevalence; severe acute respiratory syndrome coronavirus 2; viruses; zoonoses.
Figures


Similar articles
-
Seroprevalence of SARS-CoV-2 Infection in Portugal in May-July 2020: Results of the First National Serological Survey (ISNCOVID-19).Acta Med Port. 2021 Feb 1;34(2):87-94. doi: 10.20344/amp.15122. Epub 2021 Feb 1. Acta Med Port. 2021. PMID: 33641702
-
SARS-CoV-2 seroprevalence in Portugal following the third epidemic wave: results of the second National Serological Survey (ISN2COVID-19).Infect Dis (Lond). 2022 Jun;54(6):418-424. doi: 10.1080/23744235.2021.2025421. Epub 2022 Jan 13. Infect Dis (Lond). 2022. PMID: 35023439
-
Comparative Effectiveness of COVID-19 Vaccines in Preventing Infections and Disease Progression from SARS-CoV-2 Omicron BA.5 and BA.2, Portugal.Emerg Infect Dis. 2023 Mar;29(3):569-575. doi: 10.3201/eid2903.221367. Epub 2023 Feb 3. Emerg Infect Dis. 2023. PMID: 36737101 Free PMC article.
-
Rapid Increase of Community SARS-CoV-2 Seroprevalence during Second Wave of COVID-19, Yaoundé, Cameroon.Emerg Infect Dis. 2022 Jun;28(6):1233-1236. doi: 10.3201/eid2806.212580. Epub 2022 Apr 26. Emerg Infect Dis. 2022. PMID: 35470795 Free PMC article.
-
Seroprevalence of SARS-CoV-2-specific antibodies in cancer outpatients in Madrid (Spain): A single center, prospective, cohort study and a review of available data.Cancer Treat Rev. 2020 Nov;90:102102. doi: 10.1016/j.ctrv.2020.102102. Epub 2020 Sep 1. Cancer Treat Rev. 2020. PMID: 32947121 Free PMC article. Review.
Cited by
-
Effectiveness of a single COVID-19 mRNA vaccine dose in individuals with prior SARS-CoV-2 infection: a systematic review.Commun Med (Lond). 2025 May 3;5(1):151. doi: 10.1038/s43856-025-00882-y. Commun Med (Lond). 2025. PMID: 40319136 Free PMC article.
-
Characterization of the SARS-CoV-2 antibody landscape in Norway in the late summer of 2022: high seroprevalence in all age groups with patterns of primary Omicron infection in children and hybrid immunity in adults.BMC Infect Dis. 2024 Aug 20;24(1):841. doi: 10.1186/s12879-024-09670-w. BMC Infect Dis. 2024. PMID: 39164637 Free PMC article.
-
Prevalence of SARS-CoV-2-specific antibodies in a sample of the Lithuanian population-based study in Spring 2023.Heliyon. 2024 Apr 12;10(8):e29343. doi: 10.1016/j.heliyon.2024.e29343. eCollection 2024 Apr 30. Heliyon. 2024. PMID: 38681561 Free PMC article.
-
Pediatric humoral immune responses and infection risk after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and two-dose vaccination during SARS-CoV-2 omicron BA.5 and BN.1 variants predominance in South Korea.Front Immunol. 2023 Dec 20;14:1306604. doi: 10.3389/fimmu.2023.1306604. eCollection 2023. Front Immunol. 2023. PMID: 38193075 Free PMC article.
-
SARS-CoV-2 seroprevalence among Beninese pregnant women in the third year of the pandemic.BMC Public Health. 2024 Jul 2;24(1):1762. doi: 10.1186/s12889-024-19087-4. BMC Public Health. 2024. PMID: 38956517 Free PMC article.
References
-
- Operational considerations for respiratory virus surveillance in Europe. [cited 2023 Jan 3]. https://www.ecdc.europa.eu/sites/default/files/documents/Operational-con...
-
- Kislaya I, Gonçalves P, Gómez V, Gaio V, Roquette R, Barreto M, et al.; ISN2COVID-19 Group. SARS-CoV-2 seroprevalence in Portugal following the third epidemic wave: results of the second National Serological Survey (ISN2COVID-19). Infect Dis (Lond). 2022;54:418–24. 10.1080/23744235.2021.2025421 - DOI - PubMed
-
- Kislaya I, Gonçalves P, Barreto M, Sousa R, Garcia AC, Matos R, et al.; ISNCOVID-19 Group. ISNCOVID-19 Group. Seroprevalence of SARS-CoV-2 infection in Portugal in May-July 2020: results of the first national serological survey (ISNCOVID-19). Acta Med Port. 2021;34:87–94. 10.20344/amp.15122 - DOI - PubMed
-
- Kislaya I, Gonçalves P, Ramalhete S, Barreto M, Torres AR, Gaio V, et al.; ISNCOVID-19 Group. SARS-CoV-2 seroprevalence following a large-scale vaccination campaign in Portugal: results of the National Serological Survey, September–November 2021. Acta Med Port. 2023;36:5–14. 10.20344/amp.18528 - DOI - PubMed
-
- National Institute of Health Doutor Ricardo Jorge. Genetic diversity of the novel coronavirus SARS-CoV-2 (COVID-19) in Portugal. August 23th 2022 report. Lisbon (Portugal): The Institute; 2022.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous